Katsukunya Jonathan N, Jones Erika, Soko Nyarai D, Blom Dirk, Sinxadi Phumla, Rayner Brian, Dandara Collet
Division of Human Genetics, Department of Pathology, Institute of Infectious Disease and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town, Cape Town 7700, South Africa.
SAMRC/UCT Platform for Pharmacogenomics Research and Translation, South African Medical Research Council, Cape Town 7501, South Africa.
J Pers Med. 2024 Jun 21;14(7):664. doi: 10.3390/jpm14070664.
Resistant hypertension (RHTN) prevalence ranges from 4 to 19% in Africa. There is a paucity of data on the role of genetic variation on RHTN among Africans. We set out to investigate the role of polymorphisms in , , , , and , on RHTN susceptibility among South Africans. Using a retrospective matched case-control study, 190 RHTN patients (cases: blood pressure (BP) ≥ 140/90 mmHg on ≥3 anti-hypertensives or BP < 140/90 mmHg on >3 anti-hypertensives) and 189 non-RHTN patients (controls: <3 anti-hypertensives, BP < 140/90 or ≥140/90 mmHg), 12 single nucleotide polymorphisms were genotyped using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), quantitative PCR and Sanger sequencing. Genetic association analyses were conducted using the additive model and multivariable logistic regression. Homozygosity for rs776746C/C genotype ( = 0.02; OR: 0.44; CI: 0.22-0.89) was associated with reduced risk for RHTN. Homozygous rs1801252G/G ( = 0.02; OR: 3.30; CI: 1.17-10.03) and rs4149601A/A genotypes ( = 0.001; OR: 3.82; CI: 1.67-9.07) were associated with increased risk for RHTN. Carriers of the of rs1801252-rs1801253 G-C haplotype had 2.83-fold odds of presenting with RHTN ( = 0.04; OR: 2.83; CI: 1.05-8.20). These variants that are associated with RHTN may have clinical utility in the selection of antihypertensive drugs in our population.
在非洲,顽固性高血压(RHTN)的患病率在4%至19%之间。关于非洲人基因变异在RHTN中的作用的数据很少。我们着手研究南非人中,、、、、和基因多态性对RHTN易感性的作用。采用回顾性匹配病例对照研究,选取190例RHTN患者(病例组:使用≥3种抗高血压药物时血压(BP)≥140/90 mmHg或使用>3种抗高血压药物时BP<140/90 mmHg)和189例非RHTN患者(对照组:<3种抗高血压药物,BP<140/90或≥140/90 mmHg),使用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)、定量PCR和桑格测序对12个单核苷酸多态性进行基因分型。使用加性模型和多变量逻辑回归进行基因关联分析。rs776746C/C基因型的纯合性(=0.02;OR:0.44;CI:0.22-0.89)与RHTN风险降低相关。rs1801252G/G纯合子(=0.02;OR:3.30;CI:1.17-10.03)和rs4149601A/A基因型(=0.001;OR:3.82;CI:1.67-9.07)与RHTN风险增加相关。rs1801252-rs1801253 G-C单倍型的携带者患RHTN的几率为2.83倍(=0.04;OR:2.83;CI:1.05-8.20)。这些与RHTN相关的变异可能在我们人群中抗高血压药物的选择方面具有临床应用价值。